Huma Wins a Global Recognition Award 2026
Dan Vahdat was completing his PhD at Johns Hopkins when he identified the problem behind Huma. Clinical teams had sophisticated tools and deep commitment — and lost all visibility into patients the moment they were discharged. Furthermore, he had grown up in a family of physicians who experienced this loss repeatedly. Vahdat founded Huma to close that gap. Today, Huma’s platform has engaged over 50 million patients, is deployed in 5,000+ hospitals across 70+ countries, and supports 15 of the world’s top 20 pharmaceutical companies.
Furthermore, Huma is the only configurable, disease-agnostic digital health platform with simultaneous clearance in six regulatory jurisdictions — FDA, EU MDR, MHRA, TGA, Saudi FDA, and India CDSCO. Additionally, Hi Scribe — the generative AI documentation tool — is already live across 870 UK practices, and Huma ranked #25 in the Sunday Times 100 Tech 2026. For that platform and that mission, Huma has earned a 2026 Global Recognition Award.
Technical Innovation and Architecture
The Huma Cloud Platform integrates five layers — remote patient monitoring, decentralized clinical trials, Hi Scribe AI documentation, Huma Intelligence agentic AI, and direct-to-consumer virtual care — into a single, governed data model. Furthermore, the regulatory architecture is the most defensible technical asset: FDA Class II and EU MDR Class IIb as a disease-agnostic platform means partners inherit global clearance without separate regulatory programs. Consequently, Huma removes 2–5 years and tens of millions from every new deployment. Additionally, the low-code development environment enables partner organizations to build new regulated applications on existing HCP infrastructure — a developer ecosystem compounding total clinical value.
50 Million Patients, Six Markets, 15 Top Pharma
Huma’s commercial scale is the most comprehensive among healthcare AI companies in Europe. Specifically: 50 million patients, 5,000+ hospitals, 15 of the 20 top pharma companies, and national programs in NHS England, NHS Wales, Germany, Greece, and the UAE. Furthermore, January 2026’s India CDSCO Class C clearance opened access to 1.5 billion additional people. Additionally, Hi Scribe — powered by 60+ million NHS eConsult consultations — is already serving 10 million UK patients across 870 practices. Consequently, Huma is simultaneously the leading clinical AI documentation platform and the most deployed remote monitoring and clinical trial platform in Europe.
Founding Vision and Johns Hopkins Origin
Dan Vahdat’s PhD at Johns Hopkins — combined with a family background in medicine — gave him a clinician’s understanding of what patients actually need: platforms that generate specific, actionable, clinically meaningful data that change physician decisions at the point of care. Furthermore, Chief Medical Officer Dr. Mert Aral brings clinical governance depth that distinguishes Huma from pure software companies — explicitly framing the platform as “a game changer for tackling inconsistency in care quality at scale.” Additionally, Dan Vahdat has been recognized in the Sunday Times 100 Tech 2026, CNBC, Forbes, and by the WEF. Consequently, Huma holds both the founder vision and the clinical governance architecture that enterprise healthcare procurement requires.
Capital and Strategic Investor Validation
The $130M Series C — led by Leaps by Bayer and Hitachi Ventures, with Samsung, Sony, Unilever, Nikesh Arora, and Michael Diekmann — is the most strategically diverse healthcare AI investor syndicate in European digital health history. Furthermore, Vahdat’s statement that most of the Series B remained in the bank at Series C confirms the company’s extraordinary capital efficiency as it scaled to 50 million patients and national government contracts simultaneously. Consequently, Huma enters its next growth phase from a position of both platform scale and financial discipline.
Industry Impact and Future Vision
Healthcare AI is at an inflection point. NHS England guidance supporting AI documentation, FDA SaMD clearance, and Huma’s 50M patient data foundation create the conditions for system-level transformation — not pilots. Furthermore, HCP is designed precisely for this moment: “Deploy AI and agentic AI across the organisation as systems connect to HCP and data becomes governed and unified.” Consequently, Huma is building the infrastructure layer every health system needs to operate safely in the age of healthcare AI.
Three growth vectors compound simultaneously: India’s 1.5 billion patients, Hi Scribe’s global expansion from 870 UK practices, and the Wheel joint venture’s direct-to-consumer channel. Most importantly, every patient enrolled and every consultation documented compounds the data foundation, making Huma’s clinical AI more capable and more irreplaceable. Huma earns the 2026 Global Recognition Award for building the regulated healthcare AI infrastructure that brings the best care to everyone — from the world’s richest systems to its most underserved populations.
Huma Cloud Platform (HCP): five-layer healthcare AI infrastructure — remote monitoring, decentralized trials, Hi Scribe, Huma Intelligence agentic AI, direct-to-consumer virtual care — in one governed data model
Six-jurisdiction simultaneous SaMD clearance: FDA Class II, EU MDR Class IIb, MHRA, TGA, Saudi FDA, India CDSCO — world’s most regulated configurable digital health platform; partners inherit global clearance instantly
Hi Scribe AI documentation: generative AI auto-generating structured medical notes and billing codes from consultations — powered by 60M+ NHS eConsult interactions; direct write-back to EMIS and SystmOne EHR
Huma Intelligence (Hi) agentic AI: advanced risk assessment, disease prediction, automated clinical decision support — AI layer operating across all HCP-connected modules with governed, unified patient data
Disease-agnostic architecture: same platform monitors heart failure, diabetes, COPD, oncology, rare diseases, and any new indication — no disease-specific regulatory clearance required for partners
Low-code development environment: partners build new regulated software applications on HCP infrastructure — eliminating the full-stack development cost while inheriting Huma’s regulatory clearance
50 million patients engaged: largest patient engagement base of any European healthcare AI platform — active across 70+ countries, not a theoretical pipeline
5,000+ hospitals and clinics deployed: production-scale clinical deployment across six national health systems simultaneously
15 of world’s top 20 pharma companies: decentralized clinical trial platform trusted by the majority of the world’s largest pharmaceutical research organizations
Hi Scribe live: 870 UK primary care practices, ~10 million patients — already the most widely deployed AI documentation tool in UK primary care at launch
India CDSCO Class C (January 2026): first configurable disease-agnostic SaMD platform cleared in India — potential impact on 1.5 billion people in world’s most populous nation
Sunday Times 100 Tech 2026, #25: one of Britain’s fastest-growing private technology companies — independent growth validation beyond health technology sector recognition
Regulatory inheritance model: partners launch regulated programs in weeks not years — removes the single largest time and capital barrier in digital health program development
Leaps by Bayer + Hitachi + Samsung + Sony + Unilever Series C: pharma strategic capital + industrial AI + consumer hardware + entertainment AI + FMCG wellness — most strategically diverse European digital health Series C syndicate
Nikesh Arora + Michael Diekmann as individual investors: former SoftBank President and former Allianz Chairman simultaneously — technology ecosystem + financial services conviction in Huma’s platform at the highest individual credibility level
National government partnerships: NHS England, NHS Wales, Germany national health system, Greece national health program, UAE — five sovereign health systems deploying HCP as critical health infrastructure
eConsult acquisition: 60M+ NHS primary care consultations providing the most credible UK clinical language model training dataset — AI documentation asset no competitor can replicate without decades of NHS deployment
Wheel joint venture (January 2025): combining Huma’s 50M patient platform with Wheel’s 6M virtual care visits and 16M messages — creating the most comprehensive US direct-to-consumer digital health Platform-as-a-Service
Capital efficiency: most of Series B funding still in bank at Series C close — Huma scaled to 50M patients and national government contracts without burning institutional capital at industry-standard rates
Low-code partner tooling: health systems and pharma companies configure and launch disease-specific programs on HCP without full-stack engineering teams — democratizing regulated digital health program deployment
Direct EHR integration: Hi Scribe writes structured notes directly into EMIS and SystmOne — no manual data transfer, no workflow change for clinicians, immediate adoption within existing practice infrastructure
870 practices and counting: Hi Scribe adopted at scale within weeks of launch — rapid deployment velocity confirmed across primary care system with minimal implementation friction
Wearable and smartphone compatibility: patients submit health data through consumer devices they already own — no medical hardware purchase required for remote monitoring program enrollment
Clinician burden reduction: documentation consuming a third of global clinical time reduced by Hi Scribe — giving clinicians back the time that patient care, not admin, demands
Healthcare equity founding mission: “bring the best care to everyone, from the richest families to the poorest” — the most explicitly articulated equity mission of any European healthtech company
India 1.5 billion patient access: CDSCO Class C clearance not a commercial optimization but a deliberate commitment to the world’s most underserved large healthcare market
NHS public health anchor: NHS England and NHS Wales deployments serve populations who cannot access premium private healthcare — public health infrastructure at the core of the commercial model
Hospital-at-home equity: remote patient monitoring enabling patients in rural, mobility-limited, or resource-constrained settings to receive the same clinical insight as patients in premium urban hospitals
Clinical AI safety governance: Dr. Mert Aral as CMO embedding clinical evidence standards and patient safety at the C-suite level — not delegated to compliance teams
Documentation burden relief for clinicians: Hi Scribe, reducing the third of clinical time spent on administration — directly addressing workforce burnout, the most pressing human sustainability crisis in global healthcare
